Evidence map›Paper›PMID 30048637›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2018

Corrigendum to 'Concomitant delivery of paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy' NANO 14 (2018) 1301-1313.

Dikshi Gupta, Manoj Kumar, Priyanka Tyagi, Sumeet Kapoor, Amit Tyagi, Tarani Kanta Barman, Surender Kharbanda, Donald Kufe, Harpal Singh

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Improved in vivo targeting of BCL-2 phenotypic conversion through hollow gold nanoshell delivery.Apoptosis : an international journal on programmed cell death · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Dikshi GuptaCentre for Biomedical Engineering, Indian Institute of Technology, HauzKhas, New Delhi, 110 016, India. Electronic address: gupta.dikshi@gmail.com.
Manoj KumarCentre for Biomedical Engineering, Indian Institute of Technology, HauzKhas, New Delhi, 110 016, India.
Priyanka TyagiCentre for Biomedical Engineering, Indian Institute of Technology, HauzKhas, New Delhi, 110 016, India.
Sumeet KapoorCentre for Biomedical Engineering, Indian Institute of Technology, HauzKhas, New Delhi, 110 016, India.
Amit TyagiInstitute of Nuclear Medicine & Allied Sciences, DRDO, Timarpur, Delhi, 110 054, India.
Tarani Kanta BarmanCentre for Biomedical Engineering, Indian Institute of Technology, HauzKhas, New Delhi, 110 016, India.
Surender KharbandaDepartment of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, MA 02215, USA.
Donald KufeDepartment of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, MA 02215, USA.
Harpal SinghCentre for Biomedical Engineering, Indian Institute of Technology, HauzKhas, New Delhi, 110 016, India. Electronic address: harpal@cbme.iitd.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID30048637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.